Hengrui Pharma Partners with Medidata to Accelerate Global Drug Research
November 15 2018 - 8:30AM
Business Wire
Leading Sponsor in China to Deliver Innovative
Therapies to Patients Worldwide with Medidata Cloud
News summary:
- Hengrui adds Medidata Rave EDC, RTSM,
Coder, Safety Gateway and Edge CTMS to support emerging market
strategy
- Medidata Cloud enables unified data
management for global clinical trial expansion
- One of the largest China-based pharma
partners with Medidata to make new global treatment
breakthroughs
Medidata (NASDAQ: MDSO) announced that Hengrui Pharma, one of
China’s largest sponsors, recently adopted Medidata Cloud, the
Intelligent Platform for Life Sciences, to accelerate global drug
research.
Hengrui selected the Medidata cloud platform in the third
quarter of this year to unify data management and navigate
international complexities. With Medidata’s unrivaled global
expertise, the company will:
- Unify clinical trials and reduce risk
with a single source for data entry
- Streamline study operations, planning
and execution
- Automate reporting of adverse
events
- Standardize data on the Medidata Cloud
in support of global regulatory compliance requirements
“Medidata will enable us to make a bigger footprint globally and
deliver smarter treatments to patients,” said Jianjun Zou, chief
medical officer, Hengrui Pharma. “Only Medidata’s comprehensive
offerings can support us as we expand our drug therapies to
patients around the world. We are confident that Medidata’s
exceptional cloud platform and deep understanding of both China and
global regions will accelerate our drug development.”
Medidata’s end-to-end solutions provide a clear view into all
clinical trial processes, including study planning and execution.
Hengrui, named by Forbes as one of the 100 most innovative
companies, will deliver new treatments to patients globally
with:
- Rave EDC: the world’s leading solution
for capturing, managing and reporting patient data
- Rave RTSM: single source of data to
improve data quality and risk reduction in randomization and trial
supply management
- Rave Coder: cloud application that
streamlines and centralizes medical coding
- Rave Safety Gateway: automate adverse
events (AEs) and serious adverse events (SAEs) to reduce error and
protect patients
- Edge CTMS: modern CTMS system for
planning, conducting and monitoring studies
“We are proud to partner with Hengrui Pharma, one of the leading
pharma companies in China,” said Jim Xu, general manager of
Medidata China. “This new relationship further cements our
leadership in the region. The Medidata Cloud supports the entire
ecosystem of data management, and is why we are uniquely positioned
to empower local partners, like Hengrui Pharma, to elevate their
clinical research to a higher global standard.”
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181115005471/en/
Medidata:Investors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024